Skip to main content
Log in

A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease

  • Original Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Background

Diverticular disease is a significant burden on healthcare systems that is managed, surgically or medically, mainly as an emergency or acute condition. There are no standardized treatment recommendations for symptomatic uncomplicated disease. We hypothesized that a probiotic would reduce abdominal pain in such patients.

Methods

We conducted a single-center, double-blind, placebo-controlled trial of probiotic treatment (Symprove) in adult patients with moderate-to-severe chronic, non-acute symptomatic diverticular disease. 143 patients were randomized to receive 1 mL/kg/day of probiotic liquid (N = 72) or placebo (N = 71) daily for 3 months. The primary endpoint was abdominal pain severity. Secondary endpoints consisted of the change in the frequency of eight abdominal symptoms and the level of intestinal inflammation (fecal calprotectin).

Results

120 patients completed the trial. Abdominal pain score, the primary end point, decreased in both groups, but no significant difference between the groups was found (P = 0.11). In relation to placebo, the probiotic significantly decreased the frequency of four of the eight secondary endpoints: constipation, diarrhea, mucorrhea, and back pain (P < 0.04). No significant differences were found in frequency of abdominal pain, PR bleeding, dysuria, and bloating.

Conclusions

Multi-strain liquid probiotic did not improve abdominal pain scores significantly, but significantly improved the frequency of four other symptoms associated with chronic, non-acute symptomatic diverticular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Angriman I, Scarpa M, Castagliuolo I (2014) Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 20:9665–9674

    Article  PubMed  PubMed Central  Google Scholar 

  • Boostrom SY, Wolff BG, Cima RR, Merchea A, Dozois EJ, Larson DW (2012) Uncomplicated diverticulitis, more complicated than we thought. J Gastrointest Surg 16:1744–1749

    Article  PubMed  Google Scholar 

  • Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K et al (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11:1614–1619

    Article  PubMed  Google Scholar 

  • Cuomo R, Barbara G, Andreozzi P, Bassotti GC, Asetti T, Grassini M et al (2013) Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 43:1147–1155

    PubMed  Google Scholar 

  • Dai C, Jiang M (2012) The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 59:67–72

    PubMed  Google Scholar 

  • Daniels L, Philipszoon LE, Boermeester MA (2014) A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. Dis Colon Rectum 57:539–543

    Article  PubMed  Google Scholar 

  • Hall JF (2014) The microbiome and diverticulitis: a new target for medical therapy? Dis Colon Rectum 57:544–545

    Article  PubMed  Google Scholar 

  • Hobson KG, Roberts PL (2004) Etiology and pathophysiology of diverticular disease. Clin Colon Rectal Surg 17:147–153

    Article  PubMed  PubMed Central  Google Scholar 

  • Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I (2014) Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 20:1192–1210

    Article  PubMed  PubMed Central  Google Scholar 

  • Humes DJ, Simpson J, Smith J, Sutton P, Zaitoun A, Bush D et al (2012) Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 24:318-e163

    Article  PubMed  Google Scholar 

  • Kvasnovsky CL, Papagrigoriadis S (2015) Symptoms in patients with diverticular disease should not be labelled as IBS. Int J Colorectal Dis 30:995

    Article  PubMed  Google Scholar 

  • Kvasnovsky CL, Bjarnason I, Papagrigoriadis S (2015) What colorectal surgeons should know about probiotics: a review. Colorectal Dis 17:840–848

    Article  CAS  PubMed  Google Scholar 

  • Lab tests online (2015) https://labtestsonline.org/understanding/analytes/gfr/tab/test/. 30 July 2015

  • Lahner E, Esposito G, Zullo A, Hassan C, Cannaviello C, Paolo MC et al (2012) High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 18:5918–5924

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marranzino G, Villena J, Salva S, Alvarez S (2012) Stimulation of macrophages by immunobiotic Lactobacillus strains: influence beyond the intestinal tract. Microbiol Immunol 56(11):771–781

    Article  CAS  PubMed  Google Scholar 

  • Marshall JK, Thabane M, Borgaonkar MR, James C (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460

    Article  PubMed  Google Scholar 

  • Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, Walkerton Health Study Investigators (2010) Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59:605–611

    Article  PubMed  Google Scholar 

  • Moher D, Schulz KF, Altman DG, CONSORT group (Consolidated Standards of Reporting Trials) (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657–662

    Article  CAS  PubMed  Google Scholar 

  • Morken MH, Lind RA, Valeur J, Wilhelmsen I, Berstad A (2009) Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: a case control study. Scand J Gastroenterol 44:308–313

    Article  PubMed  Google Scholar 

  • Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314:779–782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Painter NS, Burkitt DP (1971) Diverticular disease of the colon: a deficiency disease of Western civilization. Br Med J 2:450–454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ et al (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–1187

    Article  PubMed  PubMed Central  Google Scholar 

  • Roland M, Torgerson DJ (1998) Understanding controlled trials: what are pragmatic trials? BMJ 316(7127):285 (Clinical research ed)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S et al (2011) Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 23:479–488

    Article  Google Scholar 

  • Sisson G, Ayis S, Sherwood RA, Bjarnason I (2014) Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther 40:51–60

    Article  CAS  PubMed  Google Scholar 

  • Sisson G, Hayee B, Bjarnason I (2015) Assessment of a multi strain probiotic (Symprove) in IBD. Gastroenterology 148:S-531

    Article  Google Scholar 

  • Spiller R (2012) Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 30:64–69

    Article  PubMed  Google Scholar 

  • Spiller R (2014) New thoughts on the association between diverticulosis and irritable bowel syndrome. Am J Gastroenterol 109:1906–1908

    Article  PubMed  Google Scholar 

  • Stollman N, Magowan S, Shanahan F, Quigley EM, DIVA Investigator Group (2013) A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 47(7):621–629. doi:10.1097/MCG0b013e31828003f6

    Article  CAS  PubMed  Google Scholar 

  • Tibble JSG, Foster R, Sherwood R, Fagerhol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G et al (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease–a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38:741–751

    Article  CAS  PubMed  Google Scholar 

  • Tursi A, Elisei W, Picchio M, Brandimarte G (2014) Increased faecal calprotectin predicts recurrence of colonic diverticulitis. Int J Colorectal Dis 29:931–935

    Article  PubMed  Google Scholar 

  • Wolff BG, Boostrom SY (2012) Prophylactic resection, uncomplicated diverticulitis, and recurrent diverticulitis. Dig Dis 30:108–113

    Article  PubMed  Google Scholar 

  • Yamada EI, Namori M, Uchida E, Tanida E, Izumi M, Takeshita K et al (2014) Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol 109:1900–1905

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the patients and staff at the Diverticular Disease clinic at King’s College Hospital, especially Ingvar Bjarnason for his assistance.

Author information

Authors and Affiliations

Authors

Contributions

Guarantor of the article: Mr. Savvas Papagrigoriadis. Specific author contributions: Study conception and design: CK, IB, and SP. Acquisition of data: CK, IB, RS, and SP. Analysis and interpretation of data: CK, IB, AND, RS, and SP. Drafting of article: CK, IB, and SP. Critical revision for important intellectual content: CK, IB, AND, RS, and SP. Final approval of version to be published: CK, IB, AND, RS, and SP. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Savvas Papagrigoriadis.

Ethics declarations

Conflict of interest and source of funding

Ingvar Bjarnason has served as a speaker and advisor board member for Symprove Ltd. Authors CLK, SP, and IB worked on this clinical trial of a probiotic, Symprove, funded by King’s College Hospital, London, via an unrestricted research grant from Symprove Ltd. No funding or other support was obtained for the writing of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kvasnovsky, C.L., Bjarnason, I., Donaldson, A.N. et al. A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. Inflammopharmacol 25, 499–509 (2017). https://doi.org/10.1007/s10787-017-0363-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-017-0363-y

Keywords

Navigation